Summary.-The activity against murine anaplastic MT tumours of the chemotherapeutic agent melphalan, either alone or in combination with one of 6 nitroimidazole compounds, was assayed using an in vivo-in vitro tumour excision assay. The melphalan alone proved cytotoxic to the tumour, whereas relatively little cytotoxicity was produced by any of the nitroimidazoles alone. When the nitroimidazole were given in combination with melphalan, dose-modifying potentiation of its cytotoxicity was observed. Maximum potentiation occurred when the nitroimidazoles were given 0-30 min before the melphalan, although some potentiation was still evident when they were given up to 2 h before or after. There was no threshold in nitroimidazole dose required to produce this potentiation, the degree of potentiation increrasing with dose, albeit at a diminishing rate, to give maximum dose-modification factors of about 3.
TUMOUR HYPOXiA has long been regarded as a critical factor in the response of human tumours to radiotherapy. Only relatively recently, however, have hypoxic cells been suspected to be a resistant subpopulation in tumour response to chemotherapy (Sutherland, 1974; Hill & Stanley, 1975; Sutherland et al., 1979; Smith et al., 1979) . Such resistance could result from poor drug access, low rate of cellular proliferation or biochemical changes arising from the hypoxic state. These considerations have prompted the experimental evaluation of combinations of various chemotherapeutic drugs with agents that are selectively toxic to hypoxic cells.
Misonidazole (MISO) , currently under clinical trial as a hypoxic cell radiosensitizer, is also selectively toxic to hypoxic cells both in vitro and in vivo (Hall & Roizin-Towle, 1975; Brown, 1977) . ther, pretreatment in vitro of hypoxic cells with misonidazole renders the cells more sensitive to the cytotoxic action of some chemotherapeutic agents (Stratford et al., 1980) . Several in vivo studies have shown that MISO apparently potentiates the anti-tumour activity of some chemotherapeutic drugs, particularly alkylating agents, in a variety of experimental tumours (Clement et al., 1980; Rose et al., 1980; Tannock, 1980; Siemann, 1981; Mulcahy et al., 1981; Law et al., 1981; Martin et al., 1981; Twentyman, 1981 (Sheldon & Hill, 1977) , by subsequent monolayer cloning (McNally & Sheldon, 1977) and by subsequent soft-agar cloning Clonogenic assay.-Tumour response was assayed by a modification of the soft-agar cloning technique described by Stephens et al. (1980) . Eighteen hours after treatment, individual tumours were excised, scraped free of muscle, minced with curved scissors, weighed, suspended in 10 ml PBS, 10 mg trypsin and 0 5 mg DNase added, and rotated at 120 rev/min for 20 min in a 37°C chamber. A further 0-25 mg DNase was then added, the suspension filtered through 35,um-pore polyester mesh, centrifuged at 1000 rev/min for 5 min, resuspended in 10 ml Ham's F12 culture medium (supplemented with 15% donor calf serum, 60 ,ug/ml sodium benzyl penicillin, 100 ,ug/ml streptomycin sulphate, and 50 ,g/ml neomycin sulphate) and refractile cells counted under a light microscope. Dilutions of the single-cell suspensions for measurement of their survival were based on counts of large cells only (i.e. > 12 ,tm diameter). The appropriately diluted cells, together with 104 heavily irradiated feeder cells and , 2 5 x 108 washed August rat erythrocytes, were suspended in Iml aliquots of 0.3% noble agar in Ham's F12 medium (supplemented with 20% donor calf serum and antibiotics as described above). Each aliquot was plated into a 30mm diameter plastic tissue-culture Petri dish containing a solidified layer of 1 ml of 0-5% noble agar in Ham's F12 medium (supplement as per aliquot). Nine replicate plates prepared from each tumour were incubated for 13-15 days at 37°C in a humidified atmosphere of 5% 02, 5% CO2 and 90/ N2. The resulting tumour colonies were counted using a low power microscope. Only compact colonies of >50 cells were counted. The plating efficiency (PE) of each tumour was calculated from the ratio of the number of colonies counted to the number of cells seeded.
RESULTS
In the course of the present study 22 untreated tumours were used as controls. Because the tumours tended to grow into the body cavity accurate palpation proved difficult, and at excision the untreated control tumour weights varied from 240 to Relative to these control tumours, the cell yield/g was reduced after melphalan treatment, as shown by the scatter diagram in Fig. 1 . This reduction in cell yield has been taken into account when expressing tumour survival. In the present studies, the survival has been expressed as surviving fraction/g tumour = relative PE x relative cell yield/g. Fig. 2 shows the effect of single doses of melphalan (given 30 min after single doses of saline) on the survival of the MT tumour. The data, which show that obtained for all the melphalan controls done during the course of these experiments (as depicted by the different symbols), fit a survival curve computed by linear regression using least-squares fit analysis with N (extrapolation number) set at unity. Although the effect of melphalan was variable, it is evident that the scatter around the dose-response line occurred not from experiment to experiment, but rather from variations in individual tumour responsiveness. Consequently this dose-response line has been taken as the melphalan response for all experiments. It indicates that the MT tumour is sensitive to melphalan, a dose of 16 ,umol/kg reducing survival by a decade.
To evaluate the effect of the nitroimidazoles on this melphalan activity, they were administered at various intervals either before, or after, the melphalan. Control experiments in which saline only was given up to 3 h before or after the melphalan showed no change in the activity of the drug; indeed, similar activity was observed when the saline dose was omitted. However, each of the 6 nitroimidazoles, when given in combination with melphalan, reduced survival further. Maximum cytotoxicity occurred when the nitroimidazole was given 0-30 min before the melphalan (Fig. 3) . To economize on the number of mice, fulltime courses weie obtained only for MISO and 8799. With these compounds increased cytotoxicity still occurred when they were given up to 2 h before, or after, the melphalan. Fig. 4 shows dose-response curves for the nitroimidazoles given at 2*5 mmol/kg 30 min before the melphalan ( originating from the individual values of N, indicate that the effect of the nitroimidazole in combination with melphalan was dose-modifying. The dose-modification factors (DMF) range from 1-6 for metronidazole to 2-2 for 8799. Fig. 5 shows that although the potentiation of melphalan activity increases with misonidazole dose, the rate of increase falls. For the compound 8799 given at three-quarteers of the LD50 dose, the maximum DMF is 3. In all cases there was no evidence for a threshold dose since the response curves appear to extrapolate back to the survival fraction for the salineplus-melphalan control (horizontal dotted line). Full histograms represent ERs at 10-3 survival, smaller hatched histograms the DMFs from slope ratios; the difference reflects the nitroimidazole-only cytotoxicity. Potentiation may increase with increasing electron affinity (El7); the distribution coefficients at pH 7-4 (D) are similar-as calculated from the pKa and partition coefficient measured of un-ionized form (P).
DISCUSSION
The 6 nitroimidazoles investigated here are known to be effective hypoxiccell radiosensitizers for the MT tumour (Sheldon & Hill, 1977; Adams et al., 1982) .
They are also selectively toxic to hypoxic cells in vitro (Adams et al., 1980; Stratford, personal communication) . In the present work, the compounds when administered singly at 2-5 mmol/kg reduced MT tumourcell survival in situ by about 30% (Fig. 4) . This amount of cell kill is probably greater than might be expected on the basis of hypoxic-cell toxicity only. While the hypoxic fraction of the MT tumour has not been measured for the present implantation site, it is only 5% in sacral s.c.
tumours (McNally & Sheldon, 1977) and 7% in thigh i.m. tumours . If the hypoxic fraction for the sacral i.m. tumours is similar in magnitude, then the 3000 drop in cell-surviving fraction would imply some cytotoxic action against oxic cells also. Brown (1977) has reported that MISO alone was cytotoxic to 900% of EMT6 tumour cells, although only 300o were radiobiologically hypoxic.
Although the cytotoxic effects of the nitroimidazoles are significant, they are very small compared with the cytotoxic effect of melphalan alone. The large increase in cell kill observed for the combined treatment of nitroimidazole and melphalan compared with melphalan alone is clearly much greater than could be accounted for simply in terms of additivity of cell kill by each agent acting independently. The relative effectiveness of the nitroimidazoles as potentiators of melphalan are compared in Fig. 6 . The administered doses of each compound were chosen to achieve equimolar levels (2.5 mmol/kg). The effectiveness of each compound is defined in Fig. 6 as both enhancement ratio (ER) and dose-modification factor (DMF). The ER is defined as the ratio of the melphalan doses required to give a surviving fraction of 1_0-3 and the DMF is the ratio of the linear slopes of the respective survival curves. The small difference between the values of ER and DMF for a given drug reflects the small but significant effect of the cytotoxic effect of the nitroimidazole alone.
The table of physical-chemical properties in Fig. 6 shows values of one-electron reduction potentials representative of relative electronaffinities (E 17), octanolwater partition coefficients (P) and, where relevant, the pKa for the compounds. (Sheldon & Batten, 1982; Workman & Twentyman, 1982) indicate that effectiveness can increase with increasing lipophilicity.
Although it is known that hypoxic cytotoxicity of nitroimidazoles in vitro increases with electron affinity (Adams et al., 1980) , it is not known what influence electron affinity has on the effectiveness of a nitroimidazole to potentiate the activity of chemotherapeutic agents. However, our data in Fig. 6 do show that from left to right the overall trend is for the enhancement ratios to increase, and this does correspond to an increase in electron affinity of the compounds.
It has been reported previously that maximum potentiation of melphalan activity towards the Lewis lung carcinoma occurred when MISO was given immediately before treatment with melphalan, although some potentiation occurred when given up to 2 h before or after (Rose et al., 1980) . In the MT tumour the timing appeared less critical, full potentiation occurring for all 6 of the nitroimidazoles when given 0-30 min before the melphalan (Fig. 3) . For MISO and 8799 at least, some potentiation was still evident when the nitroimidazole was given up to 2 h before or after the melphalan.
Consideration of the mechanism of this potentiation will be dealt with in a subsequent paper. Since greater potentiation of melphalan activity has been reported in tumours than dose-limiting normal tissues (Rose et al., 1980; Clement et al., 1980) , a therapeutic gain may be anticipated clinically. Although the nitroimidazole dose mainly used here (2.5 mmol/kg) is approximately 3-fold that clinically acceptable for MISO as a radiosensitizer (Dische et al., 1977) , the absence of a threshold dose (Fig. 5) suggests that some potentiation may occur at clinically acceptable doses. Indeed, as the magni-530 tude of this effect has been reported to increase with prolonged contact time (Brown & Hirst, 1982) , the effect would be expected to be greater clinically than here because of the shorter half-lives of these agents in mice than in man.
In conclusion, the present study has shown that the activity of the alkylating agent melphalan against the anaplastic MT tumour can be potentiated by nitroimidazole compounds in a dose-modifying manner. MISO, radiobiologically the most commonly used nitroimidazole, was not the most effective potentiator of melphalan activity; of the 6 compounds investigated in this paper, the most effective compound was Ro 03-8799.
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